Drug Trial Radar · NCT01356680
HD17 for Intermediate Stage Hodgkin Lymphoma
Last checked: Nov 20, 2026Latest source record: Apr 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,100
Actual
Start
Jan 13, 2012
Primary completion
Mar 21, 2020
Study completion Mar 23, 2020
Sponsor
- Lead sponsor
- University of CologneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 19, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of progression free survival (PFS).
Conditions
- Hodgkin Lymphoma
Interventions
BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)Drug
ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)Drug
30Gy IF-RT (Involved-Field Radiotherapy)Radiation
30Gy IN-RT (Involved-Node Radiotherapy)Radiation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
1st Dept. of Medicine, Cologne University Hospital
Cologne, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.